CRISPR–Cas9 applications in T cells and adoptive T cell therapies

• Published in: Cellular & molecular biology letters Vol. 29; no. 1; pp. 52 - 25
• Main Authors: Chen, Xiaoying, Zhong, Shuhan, Zhan, Yonghao, Zhang, Xuepei
• Format: Journal Article
• Language: English
• Published: England BioMed Central 12.04.2024; BMC
• Subjects: Adoptive T cell therapy; Antigens; Autoimmune diseases; Cancer; CAR-T; Cell activation; Cell Differentiation; Cell growth; Cell therapy; Clinical trials; CRISPR; CRISPR-Cas Systems - genetics; CRISPR–Cas9; Cytokines; Genes; Genome editing; Genomes; Homeostasis; Humans; Immune checkpoint inhibitors; Immune system; Infections; Inflammation; Inflammatory diseases; Lymphocyte Activation; Lymphocytes; Lymphocytes T; Medical prognosis; Metabolism; Microenvironments; Proteins; Systems stability; T cell receptors; T cells; T-Lymphocytes; TCR-T; TIL; Transcription factors; Tumor necrosis factor-TNF; Tumors; T cells; CAR-T; TCR-T; CRISPR–Cas9; Adoptive T cell therapy; TIL

T cell immunity is central to contemporary cancer and autoimmune therapies, encompassing immune checkpoint blockade and adoptive T cell therapies. Their diverse characteristics can be reprogrammed by different immune challenges dependent on antigen stimulation levels, metabolic conditions, and the d...